This Article Full Text Full Text (PDF) CME: Take the course for this article: Intraperitoneal Chemotherapy for Women with Epithelial Ovarian Cancer eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Google Scholar Articles by Trimble, E. L. Articles by Minasian, L. PubMed PubMed Citation Articles by Trimble, E. L. Articles by Minasian, L.

Gynecologic Oncology

Intraperitoneal Chemotherapy for Women with Epithelial Ovarian Cancer

^aNational Cancer Institute, Bethesda, Maryland, USA; ^bJohns Hopkins Hospital, Baltimore, Maryland, USA

Correspondence: Correspondence: Edward L. Trimble, M.D., M.P.H., Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Boulevard, Suite 7025, MSC 7436, Bethesda, Maryland 20892-7436, USA. Telephone: 301-496-2522; Fax: 301-402-0557; e-mail: trimblet{at}ctep.nci.nih.gov

Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

In 2006, i.p. chemotherapy re-emerged as a controversial topic in debates about the optimal treatment for women with advanced epithelial ovarian cancer. In this paper, we address the rationale behind i.p. chemotherapy, the data supporting its use, the selection of appropriate patients for i.p. chemotherapy, how best to avoid and manage the toxicities observed with i.p. chemotherapy, and directions for future research.